Zura Bio went public via a SPAC merger with JATT Acquisition in a $215m deal.

Zura Bio, a clinical-stage biotechnology company, went public via a SPAC merger with JATT Acquisition, a special purpose acquisition company, in a $215m deal. “This is an important milestone for our company and investors. I am eager to work alongside the proven and experienced leadership at Zura Bio as we collectively build the next immunology leader. This transaction allows us to progress our multi-asset pipeline targeting important immunology pathways, including IL7, TSLP and IL33, with best-in-class potential to help patients in need of new therapies,” Someit Sidhu, Zura Bio CEO.